Soleno Therapeutics to Participate in Upcoming February Investor Conferences

GlobeNewswire

01-30

REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February:

Guggenheim SMID Cap Biotech Conference
Presentation Date: Thursday, February 6, 2025 at 2:00 PM ET
Presentation Format: Fireside Chat
Webcast: https://wsw.com/webcast/guggen2/slno/2028708

Oppenheimer 35^th Annual Healthcare Life Sciences Conference
Presentation Date: Tuesday, February 11, 2025 at 2:40 PM ET
Presentation Format: Corporate Presentation
Webcast: https://wsw.com/webcast/oppenheimer39/slno/2814816

A replay of both events will be available in the Investors section on the Company’s website at www.soleno.life.

About Soleno Therapeutics, Inc.

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and was granted Priority Review. For more information, please visit www.soleno.life.

Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2507630836"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2507630836\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2507630836?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-30 05:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2507630836","market":"us","top_or_hot":-1,"title":"Soleno Therapeutics to Participate in Upcoming February Investor Conferences","media":"GlobeNewswire","content":"<html><body><p>REDWOOD CITY, Calif., Jan.  29, 2025  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/SLNO\">Soleno Therapeutics</a>, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February:</p> <p><strong>Guggenheim SMID Cap Biotech Conference</strong><br/><strong>Presentation Date:</strong> Thursday, February 6, 2025 at 2:00 PM ET<br/><strong>Presentation Format:</strong> Fireside Chat<br/><strong>Webcast: </strong>https://wsw.com/webcast/guggen2/slno/2028708</p> <p><strong>Oppenheimer 35</strong><sup><strong>th</strong></sup><strong> Annual Healthcare Life Sciences Conference</strong><br/><strong>Presentation Date:</strong> Tuesday, February 11, 2025 at 2:40 PM ET<br/><strong>Presentation Format:</strong> Corporate Presentation<br/><strong>Webcast: </strong>https://wsw.com/webcast/oppenheimer39/slno/2814816</p> <p>A replay of both events will be available in the Investors section on the Company’s website at www.soleno.life.</p> <p><strong>About Soleno <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc.</strong></p> <p>Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and was granted Priority Review. For more information, please visit www.soleno.life.</p> <p><strong>Corporate Contact:</strong><br/>Brian Ritchie<br/>LifeSci Advisors, LLC<br/>212-915-2578</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/ZWI1MmU4YTgtZjZiZS00MDk0LWEzZmMtOWVjY2Q4YTU0ZDY0LTUwMDA3Mjk5OQ==/tiny/Soleno-Therapeutics.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Soleno Therapeutics to Participate in Upcoming February Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSoleno Therapeutics to Participate in Upcoming February Investor Conferences\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time smaller\">2025-01-30 05:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p>REDWOOD CITY, Calif., Jan.  29, 2025  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/SLNO\">Soleno Therapeutics</a>, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February:</p> <p><strong>Guggenheim SMID Cap Biotech Conference</strong><br/><strong>Presentation Date:</strong> Thursday, February 6, 2025 at 2:00 PM ET<br/><strong>Presentation Format:</strong> Fireside Chat<br/><strong>Webcast: </strong>https://wsw.com/webcast/guggen2/slno/2028708</p> <p><strong>Oppenheimer 35</strong><sup><strong>th</strong></sup><strong> Annual Healthcare Life Sciences Conference</strong><br/><strong>Presentation Date:</strong> Tuesday, February 11, 2025 at 2:40 PM ET<br/><strong>Presentation Format:</strong> Corporate Presentation<br/><strong>Webcast: </strong>https://wsw.com/webcast/oppenheimer39/slno/2814816</p> <p>A replay of both events will be available in the Investors section on the Company’s website at www.soleno.life.</p> <p><strong>About Soleno <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc.</strong></p> <p>Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and was granted Priority Review. For more information, please visit www.soleno.life.</p> <p><strong>Corporate Contact:</strong><br/>Brian Ritchie<br/>LifeSci Advisors, LLC<br/>212-915-2578</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/ZWI1MmU4YTgtZjZiZS00MDk0LWEzZmMtOWVjY2Q4YTU0ZDY0LTUwMDA3Mjk5OQ==/tiny/Soleno-Therapeutics.png\"/></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2025/01/29/3017568/0/en/Soleno-Therapeutics-to-Participate-in-Upcoming-February-Investor-Conferences.html","article_id":"2507630836","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2507630836","pubTimestamp":1738184700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"REDWOOD CITY, Calif., Jan.  29, 2025  (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatmen","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SLNO":"Soleno Therapeutics","PWS":"Pacer WealthShield ETF"},"translate_title":"Soleno Therapeutics将参加即将举行的二月份投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PWS":1,"SLNO":1},"content_text":"REDWOOD CITY, Calif., Jan.  29, 2025  (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February: Guggenheim SMID Cap Biotech ConferencePresentation Date: Thursday, February 6, 2025 at 2:00 PM ETPresentation Format: Fireside ChatWebcast: https://wsw.com/webcast/guggen2/slno/2028708 Oppenheimer 35th Annual Healthcare Life Sciences ConferencePresentation Date: Tuesday, February 11, 2025 at 2:40 PM ETPresentation Format: Corporate PresentationWebcast: https://wsw.com/webcast/oppenheimer39/slno/2814816 A replay of both events will be available in the Investors section on the Company’s website at www.soleno.life. About Soleno Therapeutics, Inc. Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and was granted Priority Review. For more information, please visit www.soleno.life. Corporate Contact:Brian RitchieLifeSci Advisors, LLC212-915-2578","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}